Which has preferable valuation & earnings, ABVX or MLYS?

Abivax is trading at a lower price-to-earnings ratio than Mineralys Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Abivax N/A N/A -$380.27M -$5.21 N/A Mineralys Therapeutics N/A N/A -$154.65M -$2.05 N/A

Is ABVX or MLYS more profitable?

Mineralys Therapeutics' return on equity of -27.92% beat Abivax's return on equity. Company Net Margins Return on Equity Return on Assets Abivax N/A -99.02% -70.26% Mineralys Therapeutics N/A -27.92% -26.98%

Does the media prefer ABVX or MLYS?

In the previous week, Abivax had 12 more articles in the media than Mineralys Therapeutics. MarketBeat recorded 25 mentions for Abivax and 13 mentions for Mineralys Therapeutics. Mineralys Therapeutics' average media sentiment score of 0.63 beat Abivax's score of 0.06 indicating that Mineralys Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abivax 4 Very Positive mention(s) 5 Positive mention(s) 5 Neutral mention(s) 3 Negative mention(s) 4 Very Negative mention(s) Neutral Mineralys Therapeutics 4 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is PRAX or MLYS more profitable?

Mineralys Therapeutics' return on equity of -27.92% beat Praxis Precision Medicines' return on equity. Company Net Margins Return on Equity Return on Assets Praxis Precision Medicines N/A -43.02% -40.22% Mineralys Therapeutics N/A -27.92% -26.98%

Does the media prefer CYTK or MLYS?

In the previous week, Mineralys Therapeutics had 4 more articles in the media than Cytokinetics. MarketBeat recorded 13 mentions for Mineralys Therapeutics and 9 mentions for Cytokinetics. Mineralys Therapeutics' average media sentiment score of 0.63 beat Cytokinetics' score of 0.10 indicating that Mineralys Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cytokinetics 3 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Mineralys Therapeutics 4 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer KRYS or MLYS?

In the previous week, Mineralys Therapeutics had 8 more articles in the media than Krystal Biotech. MarketBeat recorded 13 mentions for Mineralys Therapeutics and 5 mentions for Krystal Biotech. Mineralys Therapeutics' average media sentiment score of 0.63 beat Krystal Biotech's score of 0.43 indicating that Mineralys Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Krystal Biotech 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Mineralys Therapeutics 4 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, NUVL or MLYS?

Nuvalent is trading at a lower price-to-earnings ratio than Mineralys Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nuvalent N/A N/A -$425.38M -$6.06 N/A Mineralys Therapeutics N/A N/A -$154.65M -$2.05 N/A

Is NUVL or MLYS more profitable?

Mineralys Therapeutics' return on equity of -27.92% beat Nuvalent's return on equity. Company Net Margins Return on Equity Return on Assets Nuvalent N/A -40.11% -35.43% Mineralys Therapeutics N/A -27.92% -26.98%

Does the media prefer NUVL or MLYS?

In the previous week, Mineralys Therapeutics had 3 more articles in the media than Nuvalent. MarketBeat recorded 13 mentions for Mineralys Therapeutics and 10 mentions for Nuvalent. Mineralys Therapeutics' average media sentiment score of 0.63 beat Nuvalent's score of 0.03 indicating that Mineralys Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvalent 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Mineralys Therapeutics 4 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Mineralys Therapeutics (MLYS) Competitors

$23.69 -1.36 (-5.43%)

Closing price 04:00 PM Eastern

Extended Trading

$23.74 +0.05 (+0.21%)

As of 07:46 PM Eastern

Compare

MLYS vs. ABVX, PRAX, CYTK, KRYS, and NUVL

Should you buy Mineralys Therapeutics stock or one of its competitors? MarketBeat compares Mineralys Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Mineralys Therapeutics include Abivax (ABVX), Praxis Precision Medicines (PRAX), Cytokinetics (CYTK), Krystal Biotech (KRYS), and Nuvalent (NUVL). These companies are all part of the "pharmaceutical products" industry.

How does Mineralys Therapeutics compare to Abivax?

Abivax (NASDAQ:ABVX) and Mineralys Therapeutics (NASDAQ:MLYS) are both mid-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, earnings, risk, valuation, institutional ownership and profitability.

47.9% of Abivax shares are held by institutional investors. Comparatively, 84.5% of Mineralys Therapeutics shares are held by institutional investors. 18.9% of Mineralys Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Mineralys Therapeutics' return on equity of -27.92% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abivax	N/A	-99.02%	-70.26%
Mineralys Therapeutics	N/A	-27.92%	-26.98%

Abivax has a beta of 0.69, suggesting that its stock price is 31% less volatile than the broader market. Comparatively, Mineralys Therapeutics has a beta of 0.57, suggesting that its stock price is 43% less volatile than the broader market.

Abivax currently has a consensus price target of $130.08, suggesting a potential upside of 28.12%. Mineralys Therapeutics has a consensus price target of $49.33, suggesting a potential upside of 108.25%. Given Mineralys Therapeutics' higher possible upside, analysts clearly believe Mineralys Therapeutics is more favorable than Abivax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abivax	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.73
Mineralys Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Abivax is trading at a lower price-to-earnings ratio than Mineralys Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A
Mineralys Therapeutics	N/A	N/A	-$154.65M	-$2.05	N/A

In the previous week, Abivax had 12 more articles in the media than Mineralys Therapeutics. MarketBeat recorded 25 mentions for Abivax and 13 mentions for Mineralys Therapeutics. Mineralys Therapeutics' average media sentiment score of 0.63 beat Abivax's score of 0.06 indicating that Mineralys Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abivax	4 Very Positive mention(s)	5 Positive mention(s)	5 Neutral mention(s)	3 Negative mention(s)	4 Very Negative mention(s)	Neutral
Mineralys Therapeutics	4 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Mineralys Therapeutics beats Abivax on 9 of the 13 factors compared between the two stocks.

How does Mineralys Therapeutics compare to Praxis Precision Medicines?

Praxis Precision Medicines (NASDAQ:PRAX) and Mineralys Therapeutics (NASDAQ:MLYS) are both mid-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, media sentiment, valuation, institutional ownership, earnings and analyst recommendations.

In the previous week, Praxis Precision Medicines had 13 more articles in the media than Mineralys Therapeutics. MarketBeat recorded 26 mentions for Praxis Precision Medicines and 13 mentions for Mineralys Therapeutics. Mineralys Therapeutics' average media sentiment score of 0.63 beat Praxis Precision Medicines' score of -0.10 indicating that Mineralys Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Praxis Precision Medicines	3 Very Positive mention(s)	4 Positive mention(s)	8 Neutral mention(s)	5 Negative mention(s)	0 Very Negative mention(s)	Neutral
Mineralys Therapeutics	4 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Praxis Precision Medicines currently has a consensus target price of $572.72, indicating a potential upside of 125.48%. Mineralys Therapeutics has a consensus target price of $49.33, indicating a potential upside of 108.25%. Given Praxis Precision Medicines' stronger consensus rating and higher probable upside, research analysts clearly believe Praxis Precision Medicines is more favorable than Mineralys Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Praxis Precision Medicines	2 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	4 Strong Buy rating(s)	2.95
Mineralys Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Mineralys Therapeutics' return on equity of -27.92% beat Praxis Precision Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Praxis Precision Medicines	N/A	-43.02%	-40.22%
Mineralys Therapeutics	N/A	-27.92%	-26.98%

Praxis Precision Medicines has a beta of 2.71, suggesting that its stock price is 171% more volatile than the broader market. Comparatively, Mineralys Therapeutics has a beta of 0.57, suggesting that its stock price is 43% less volatile than the broader market.

67.8% of Praxis Precision Medicines shares are owned by institutional investors. Comparatively, 84.5% of Mineralys Therapeutics shares are owned by institutional investors. 2.7% of Praxis Precision Medicines shares are owned by insiders. Comparatively, 18.9% of Mineralys Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Mineralys Therapeutics has lower revenue, but higher earnings than Praxis Precision Medicines. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Mineralys Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Praxis Precision Medicines	$8.55M	828.25	-$303.27M	-$13.37	N/A
Mineralys Therapeutics	N/A	N/A	-$154.65M	-$2.05	N/A

Summary

Mineralys Therapeutics beats Praxis Precision Medicines on 8 of the 15 factors compared between the two stocks.

How does Mineralys Therapeutics compare to Cytokinetics?

Cytokinetics (NASDAQ:CYTK) and Mineralys Therapeutics (NASDAQ:MLYS) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, risk, analyst recommendations and media sentiment.

84.5% of Mineralys Therapeutics shares are owned by institutional investors. 2.6% of Cytokinetics shares are owned by insiders. Comparatively, 18.9% of Mineralys Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Mineralys Therapeutics had 4 more articles in the media than Cytokinetics. MarketBeat recorded 13 mentions for Mineralys Therapeutics and 9 mentions for Cytokinetics. Mineralys Therapeutics' average media sentiment score of 0.63 beat Cytokinetics' score of 0.10 indicating that Mineralys Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cytokinetics	3 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Mineralys Therapeutics	4 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Mineralys Therapeutics has a net margin of 0.00% compared to Cytokinetics' net margin of -784.02%. Cytokinetics' return on equity of 0.00% beat Mineralys Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytokinetics	-784.02%	N/A	-52.86%
Mineralys Therapeutics	N/A	-27.92%	-26.98%

Mineralys Therapeutics has lower revenue, but higher earnings than Cytokinetics. Mineralys Therapeutics is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytokinetics	$88.04M	101.03	-$784.96M	-$6.84	N/A
Mineralys Therapeutics	N/A	N/A	-$154.65M	-$2.05	N/A

Cytokinetics has a beta of 0.42, meaning that its stock price is 58% less volatile than the broader market. Comparatively, Mineralys Therapeutics has a beta of 0.57, meaning that its stock price is 43% less volatile than the broader market.

Cytokinetics presently has a consensus price target of $99.30, suggesting a potential upside of 38.92%. Mineralys Therapeutics has a consensus price target of $49.33, suggesting a potential upside of 108.25%. Given Mineralys Therapeutics' higher probable upside, analysts plainly believe Mineralys Therapeutics is more favorable than Cytokinetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytokinetics	1 Sell rating(s)	3 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.86
Mineralys Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Summary

Mineralys Therapeutics beats Cytokinetics on 10 of the 16 factors compared between the two stocks.

How does Mineralys Therapeutics compare to Krystal Biotech?

Krystal Biotech (NASDAQ:KRYS) and Mineralys Therapeutics (NASDAQ:MLYS) are both mid-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, media sentiment, risk, institutional ownership, earnings and analyst recommendations.

Krystal Biotech has a net margin of 53.92% compared to Mineralys Therapeutics' net margin of 0.00%. Krystal Biotech's return on equity of 19.25% beat Mineralys Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Krystal Biotech	53.92%	19.25%	17.62%
Mineralys Therapeutics	N/A	-27.92%	-26.98%

Krystal Biotech has higher revenue and earnings than Mineralys Therapeutics. Mineralys Therapeutics is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Krystal Biotech	$389.13M	22.80	$204.83M	$7.48	40.24
Mineralys Therapeutics	N/A	N/A	-$154.65M	-$2.05	N/A

Krystal Biotech has a beta of 0.53, meaning that its share price is 47% less volatile than the broader market. Comparatively, Mineralys Therapeutics has a beta of 0.57, meaning that its share price is 43% less volatile than the broader market.

In the previous week, Mineralys Therapeutics had 8 more articles in the media than Krystal Biotech. MarketBeat recorded 13 mentions for Mineralys Therapeutics and 5 mentions for Krystal Biotech. Mineralys Therapeutics' average media sentiment score of 0.63 beat Krystal Biotech's score of 0.43 indicating that Mineralys Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Krystal Biotech	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Mineralys Therapeutics	4 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

86.3% of Krystal Biotech shares are owned by institutional investors. Comparatively, 84.5% of Mineralys Therapeutics shares are owned by institutional investors. 13.1% of Krystal Biotech shares are owned by company insiders. Comparatively, 18.9% of Mineralys Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Krystal Biotech currently has a consensus target price of $324.11, suggesting a potential upside of 7.68%. Mineralys Therapeutics has a consensus target price of $49.33, suggesting a potential upside of 108.25%. Given Mineralys Therapeutics' higher possible upside, analysts clearly believe Mineralys Therapeutics is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.83
Mineralys Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Summary

Krystal Biotech beats Mineralys Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Mineralys Therapeutics compare to Nuvalent?

Nuvalent (NASDAQ:NUVL) and Mineralys Therapeutics (NASDAQ:MLYS) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership.

In the previous week, Mineralys Therapeutics had 3 more articles in the media than Nuvalent. MarketBeat recorded 13 mentions for Mineralys Therapeutics and 10 mentions for Nuvalent. Mineralys Therapeutics' average media sentiment score of 0.63 beat Nuvalent's score of 0.03 indicating that Mineralys Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuvalent	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Mineralys Therapeutics	4 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Nuvalent presently has a consensus price target of $141.24, indicating a potential upside of 55.29%. Mineralys Therapeutics has a consensus price target of $49.33, indicating a potential upside of 108.25%. Given Mineralys Therapeutics' higher probable upside, analysts clearly believe Mineralys Therapeutics is more favorable than Nuvalent.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvalent	1 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	1 Strong Buy rating(s)	2.94
Mineralys Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Mineralys Therapeutics' return on equity of -27.92% beat Nuvalent's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvalent	N/A	-40.11%	-35.43%
Mineralys Therapeutics	N/A	-27.92%	-26.98%

97.3% of Nuvalent shares are owned by institutional investors. Comparatively, 84.5% of Mineralys Therapeutics shares are owned by institutional investors. 5.0% of Nuvalent shares are owned by insiders. Comparatively, 18.9% of Mineralys Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Nuvalent has a beta of 1.15, indicating that its stock price is 15% more volatile than the broader market. Comparatively, Mineralys Therapeutics has a beta of 0.57, indicating that its stock price is 43% less volatile than the broader market.

Nuvalent is trading at a lower price-to-earnings ratio than Mineralys Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvalent	N/A	N/A	-$425.38M	-$6.06	N/A
Mineralys Therapeutics	N/A	N/A	-$154.65M	-$2.05	N/A

Summary

Mineralys Therapeutics beats Nuvalent on 9 of the 14 factors compared between the two stocks.

Get Mineralys Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MLYS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MLYS vs. The Competition

Export

Metric	Mineralys Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.07B	$3.36B	$6.49B	$12.46B
Dividend Yield	N/A	2.31%	2.67%	5.34%
P/E Ratio	-11.56	18.38	23.93	23.64
Price / Sales	N/A	298.63	517.33	112.57
Price / Cash	N/A	114.83	42.35	57.17
Price / Book	2.90	6.51	9.73	6.37
Net Income	-$154.65M	$24.09M	$3.56B	$337.36M
7 Day Performance	-24.79%	-6.98%	-3.19%	-3.07%
1 Month Performance	-19.09%	-3.57%	-0.11%	0.37%
1 Year Performance	51.66%	42.44%	25.29%	27.87%

Mineralys Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MLYS Mineralys Therapeutics	3.7023 of 5 stars	$23.69 -5.4%	$49.33 +108.2%	+61.4%	$2.07B	N/A	N/A	28	Positive News High Trading Volume
ABVX Abivax	3.7878 of 5 stars	$73.06 -43.7%	$133.15 +82.3%	+1,201.9%	$10.34B	N/A	N/A	61	Analyst Forecast Options Volume Gap Up High Trading Volume
PRAX Praxis Precision Medicines	3.2007 of 5 stars	$280.34 -16.4%	$572.72 +104.3%	+540.0%	$9.34B	N/A	N/A	110	News Coverage Analyst Forecast Analyst Revision
CYTK Cytokinetics	2.8375 of 5 stars	$71.36 -3.1%	$99.30 +39.2%	+123.0%	$9.17B	$105.82M	N/A	250
KRYS Krystal Biotech	3.1592 of 5 stars	$291.01 -2.4%	$324.11 +11.4%	+133.1%	$9.11B	$417.30M	39.33	210	Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MLYS) was last updated on 6/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Mineralys Therapeutics (MLYS) Competitors

MLYS vs. ABVX, PRAX, CYTK, KRYS, and NUVL

How does Mineralys Therapeutics compare to Abivax?

Summary

How does Mineralys Therapeutics compare to Praxis Precision Medicines?

Summary

How does Mineralys Therapeutics compare to Cytokinetics?

Summary

How does Mineralys Therapeutics compare to Krystal Biotech?

Summary

How does Mineralys Therapeutics compare to Nuvalent?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MLYS vs. The Competition

Mineralys Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Mineralys Therapeutics (MLYS) Competitors

MLYS vs. ABVX, PRAX, CYTK, KRYS, and NUVL

How does Mineralys Therapeutics compare to Abivax?

Do institutionals and insiders hold more shares of ABVX or MLYS?

Is ABVX or MLYS more profitable?

Which has more volatility and risk, ABVX or MLYS?

Do analysts recommend ABVX or MLYS?

Which has preferable valuation & earnings, ABVX or MLYS?

Does the media prefer ABVX or MLYS?

Summary

How does Mineralys Therapeutics compare to Praxis Precision Medicines?

Does the media prefer PRAX or MLYS?

Do analysts rate PRAX or MLYS?

Is PRAX or MLYS more profitable?

Which has more risk and volatility, PRAX or MLYS?

Do insiders and institutionals have more ownership in PRAX or MLYS?

Which has preferable valuation and earnings, PRAX or MLYS?

Summary

How does Mineralys Therapeutics compare to Cytokinetics?

Do insiders & institutionals have more ownership in CYTK or MLYS?

Does the media prefer CYTK or MLYS?

Is CYTK or MLYS more profitable?

Which has stronger valuation & earnings, CYTK or MLYS?

Which has more risk & volatility, CYTK or MLYS?

Do analysts rate CYTK or MLYS?

Summary

How does Mineralys Therapeutics compare to Krystal Biotech?

Is KRYS or MLYS more profitable?

Which has better earnings and valuation, KRYS or MLYS?

Which has more volatility & risk, KRYS or MLYS?

Does the media prefer KRYS or MLYS?

Do institutionals and insiders have more ownership in KRYS or MLYS?

Do analysts rate KRYS or MLYS?

Summary

How does Mineralys Therapeutics compare to Nuvalent?

Does the media prefer NUVL or MLYS?

Do analysts prefer NUVL or MLYS?

Is NUVL or MLYS more profitable?

Do institutionals & insiders have more ownership in NUVL or MLYS?

Which has more risk & volatility, NUVL or MLYS?

Which has higher earnings & valuation, NUVL or MLYS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MLYS vs. The Competition

Mineralys Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools